Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen is a recombinant lipidated factor H binding protein (fHBP) from subfamily A of N. meningitidis serogroup B. It is one of two key antigens in the bivalent vaccine Trumenba (the other being the B01 variant), designed for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. The vaccine works by inducing antibodies that target fHBP on the surface of N. meningitidis, promoting complement-mediated bactericidal activity and providing broad protection against diverse strains expressing this antigen[4][6]. Developed as part of a strategy to address the high variability among MenB strains, this component ensures coverage against isolates expressing fHBP subfamily A variants[4][9]. The primary indication is prevention of invasive MenB disease in adolescents and young adults.
- Brand names
- TrumenbaPenbraya
- Other names
- Neisseria meningitidis group B recombinant LP2086 A05 protein variant antigenrLP2086 A05rLP-2086 A05rLP 2086 A05
02
Targets
fHbp (Factor H-binding protein)
Beyond the preview
Go deeper on Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen.